News

15/11/2016 · Corporate
Reinventing the Health sector start-up financing model
Kurma Partners, a French venture capital company specialising in the Life Sciences sector, today presents its investment convictions to encourage innovation and accelerate the creation of new Health-sector companies. [...]
16/10/2016 · Participation
Kurma Partners and Idinvest Partners launches Dynacure a new company specialized in rare neuromuscular diseases
Kurma announced on Monday the 24th of October 2016, that they have entered into a collaboration agreement with Conectus and Ionis Pharmaceutical to launch Dynacure, a Strasbourg-based biotech specializing in the treatment of rare neuromuscular disorders. [...]
14/10/2015 · Participation
Kurma Partners announces investments in Asceneuron SA and Minoryx Therapeutics SL
Kurma Partners, a key European player in the financing of Innovation in Healthcare, announces two new investments of Kurma Biofund II [...]
23/06/2015 · Corporate
Kurma Partners expands its investment team with the appointment of Alain Horvais and Philippe Peltier as Partners and announces the promotion of Vanessa Malier as Managing Partner
Paris, June 23th 2015. Alain Horvais and Philippe Peltier join Kurma Partners to serve as Partners in charge of the management of Kurma Diagnostics [...]
08/06/2015 · Participation
KURMA ANNOUNCES THE FIRST INVESTMENT OF THEIR NEWLY LAUNCHED DIAGNOSTICS FUNDS IN THE START UP COMPANY BIOSERENITY
The French start-up specialized in wearable medical device solutions raises 3 million Euros in a Seed round to grow in the medical diagnostic field. [...]
26/05/2015 · Corporate
Kurma Partners announces the launch of its third fund Kurma Diagnostics (KDx)
The European Investment Fund (EIF), Fonds National d’Amorçage (FNA) managed by Bpifrance as part of the French government’s Investments for [...]
12/05/2015 · Participation
Kurma Biofund I portfolio company AM Pharma enters into a major transaction with Pfizer
Kurma Partners announces that Pfizer acquires minority interest in AM Pharma, a Kurma Biofund I portfolio company, and secures an option to [...]
12/03/2015 · Corporate
Kurma Partners has moved
Our new head office is located at 24 Rue Royale - 75008 Paris, France. Our office number is now: +33 (0)1 84 860 861 [...]
09/01/2015 · Corporate
KURMA Partners invests in Orphazyme ApS
KURMA Partners invests in Orphazyme ApS, a leading European biopharmaceutical company developing Heat Shock Protein based treatment for lysosomal storage diseases and [...]
08/12/2014 · Corporate
Kurma Biofund, a recently launched life science fund, announces a new relationship with Imperial Innovations plc
Kurma Biofund (Kurma) is a new venture capital fund based in Paris and dedicated to innovations in Life Sciences and Healthcare [...]
06/12/2014 · Participation
MEIOGENIX SAS, A FRENCH GENOMIC START-UP COMPANY, RAISES 1,2M € FROM INVESTORS
Meiogenix SAS, a French start-up biotech company developing of a new genomic technology, closed its first round of financing of 1,2M € [...]
02/12/2014 · Participation
Imperial Innovations and Kurma BioFund I conclude £0.93m seed investment in Indigix Ltd
Imperial Innovations Group plc (AIM: IVO, or „Innovations‟), a leading technology commercialisation and investment company [...]
02/12/2014 · Participation
KURMA Partners invests in Xeltis, a leading regenerative medicine company with first product targeting orphan and severe cardiac malformations
Kurma Partners, a key European player in the financing of Innovation in Healthcare, announces its investment in Xeltis, a private Swiss/Dutch [...]
29/11/2014 · Participation
Idinvest Partners and Kurma Life Sciences Partners announce the IPO of Zealand Pharma A /S
On Tuesday November 23rd, Zealand Pharma A/S (Zealand Pharma)initiated its first trading day on the Nasdaq OMX Copenhagen exchange. [...]
26/11/2014 · Participation
Idinvest Partners et Kurma Partners annoncent la cession de Prosensa
BioMarin et Prosensa ont annoncé lundi 24 novembre matin l’intention pour de la société américaine d’acquérir 100% des actions de Prosensa [...]
24/11/2014 · Corporate
Natixis Private Equity and CDC Entreprises announce the launching of Kurma Biofund
Only available in french [...]
25/10/2014 · Corporate
Kurma announces a consulting agreement with IDinvest Partners
The agreement concerns a portion of the Biotech portfolio managed by IDInvest Partners, representing 87 million Euros invested. [...]
04/10/2014 · Participation
Kurma Life Sciences Partners and the SATT Conectus Alsace unite their strengths to accelerate the new business start-up exits of the public research
Kurma Life Sciences Partners, company of venture capital spectialist of the Health and the Biotechnologies, and the SATT Conectus Alsace company of [...]
28/09/2014 · Participation
Idinvest Partners and Kurma Life Sciences Partners announce the first step of the acquisition of Novagali Pharma S.A. by Santen Pharmaceutical Co., Ltd
On Tuesday September 27th, Santen Pharmaceutical Co., Ltd. (Osaka, Japon), a leading Japanese pharmaceutical company, and [...]
24/09/2014 · Corporate
Kurma Life Sciences Partners announces that Vanessa Malier joins as Partner
Vanessa joins today Kurma Life Sciences Partners as Partner, bringing 15 years of experience in Biotech and pharmaceutical industry [...]
14/09/2014 · Participation
Kurma Life Sciences Partners and Idinvest Partners announce the EUR 29,2 Million Series D Financing of AM Pharma
Kurma Life Science Partners and Idinvest Partners today announced that they have participated in a EUR 29,2 million Series D financing round of [...]
09/07/2014 · Corporate
Kurma Life Sciences Partners and Cydan Enter Collaboration
Kurma Life Sciences Partners today announced collaboration with Cydan Development, Inc., an orphan drug accelerator that identifies strategic [...]
04/07/2014 · Participation
Kurma Life Sciences Partners and Idinvest Partners announce the success of IPO of Prosensa Holding B.V
On Friday June 28th, Prosensa Holding B.V. (Prosensa) initiated its first trading day on the Nasdaq New York, US. Prosensa [...]
03/07/2014 · Participation
Idinvest Partners cements ties with Kurma Life Sciences Partners
In keeping with their history of close collaboration, the companies announced today that Idinvest Partners was acquiring a stake in KLS Partners. [...]
29/06/2014 · Corporate
Karolinska Development and Kurma Biofund to enter strategic partnership
Karolinska Development AB and Kurma Biofund have entered into a strategic partnership, with the purpose [...]
24/06/2014 · Corporate
Cancer research technology and kurma biofund to develop new antibody platform for translational research
CANCER RESEARCH TECHNOLOGY, the commercial arm of Cancer Research UK, and Parisbased venture capital firm, Kurma [...]
20/06/2014 · Corporate
Kurma Life Sciences Partners announces the launch of Kurma Biofund II: The Orphan Initiative
KLS Partners, GlaxoSmithKline (GSK), bpifrance (CDC Entreprises), Idinvest Partners and New Enterprise Associates (NEA) are participating in the first closing (€44M). [...]
16/04/2014 · Participation
KURMA Partners invests in OxThera, first investment of its fund Kurma Biofund II
Kurma Partners, a key European player in the financing of Innovation in Healthcare and Biotechnology, announces its first investment [...]
29/03/2014 · Participation
French pathogens discovery biotechnology start –up, PathoQuest SAS, raises 2M€ with Kurma BioFund in its first round of financing
Founded in September 2010 by Professor Marc Eloit and Luc Boblet (PhD), PathoQuest SAS completed, on March 11th 2011, its first round of financing [...]
21/03/2014 · Corporate
Stevenage BioScience Catalyst and Kurma Life Sciences Partners Announce Collaboration to Stimulate Investment in Bioscience Companies
Stevenage, UK, and Paris, France, March 21 2012 - Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation [...]
21/01/2014 · Corporate
Kurma Biofund extends UK partnerships with UCL
Kurma Biofund extends UK partnerships with UCL Business plc (London) and the Institute for Child Health (University College London) [...]